)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Immix Biopharma
Immix Biopharma (IMMX) investor relations material
Immix Biopharma Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary11 Aug, 2026
Unmet medical need in AL amyloidosis
Over 30,000 U.S. patients with relapsed/refractory AL amyloidosis lack FDA-approved therapies, facing poor outcomes and limited options after frontline treatment failure.
Standard of care yields only a 0-10% complete response rate in relapsed/refractory settings, with most patients requiring second-line therapy within a year.
NXC-201: Mechanism and innovation
NXC-201 is a BCMA-targeted CAR-T cell therapy designed to eliminate dysfunctional plasma cells producing toxic light chains.
Proprietary engineering optimizes cytotoxicity, reduces non-specific activation, and minimizes cytokine release, aiming for safer and more effective treatment.
Clinical trial results and efficacy
In the U.S. NEXICART-2 trial, NXC-201 achieved a 95% complete response rate in relapsed/refractory AL amyloidosis, with rapid normalization of disease markers and 100% organ response in evaluable patients.
Responses were observed within the first week for most patients, and the complete response rate improved over time as more data matured.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Immix Biopharma
- NXC-201 Phase 2 showed 95% CR rate; $232M cash reserves support ongoing clinical expansion.IMMX
Q2 2026 - NXC-201 delivers 95% complete response in relapsed/refractory AL amyloidosis with rapid, deep organ responses.IMMXCorporate presentation
- NXC-201 achieved a 95% complete response rate in relapsed/refractory AL amyloidosis.IMMXCorporate presentation
- Q1 2026 net loss rose to $10.1M as R&D spending increased; cash reserves remain strong.IMMXQ1 2026
- NXC-201 delivers 75% complete response in relapsed/refractory AL amyloidosis with strong safety.IMMXCorporate presentation
- Shareholders to vote on nine directors and auditor ratification at the 2026 annual meeting.IMMXProxy filing
- Nine directors up for election, auditor ratification, and robust governance and compensation policies.IMMXProxy filing
- Strong clinical progress and $100M capital raise, but ongoing losses and future funding needs remain.IMMXQ4 2025
- NXC-201 delivers 75% complete response in relapsed/refractory AL amyloidosis, redefining outcomes.IMMXCorporate presentation
Next Immix Biopharma earnings date
Q3 20266 Nov, 2026
Immix Biopharma
Next Immix Biopharma earnings date
Q3 20266 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage